A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Update on obinutuzumab in the treatment of B-cell malignancies

(2014) Tim Illidge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas

(2014) Marcus Remer et al.   Immunotherapy

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

(2013) Raymund Buhmann et al.   Journal of Translational Medicine

IgBLAST: an immunoglobulin variable domain sequence analysis tool

(2013) Jian Ye et al.   NUCLEIC ACIDS RESEARCH

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Capture, crawl, cross: the T cell code to breach the blood–brain barriers

(2012) Britta Engelhardt et al.   TRENDS IN IMMUNOLOGY

The future of anti-CD20 monoclonal antibodies: are we making progress?

(2011) W. Alduaij et al.   BLOOD

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

(2011) Dirk Nagorsen et al.   EXPERIMENTAL CELL RESEARCH

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Does VEGF secreted by leukemic cells increase the permeability of blood–brain barrier by disrupting tight-junction proteins in central nervous system leukemia?

(2011) Sara Feng et al.   MEDICAL HYPOTHESES

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

(2010) Claudia Bluemel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Catumaxomab

(2010) Rolf Linke et al.   mAbs

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH